Patents Examined by Yong D. Pak
  • Patent number: 12146167
    Abstract: An enzymatically catalyzed method for producing L-glufosinate or a phosphoester of L-glufosinate can be performed. An activated L-homoserine HA is reacted with a substrate S selected from methylphosphinic acid and the esters of methylphosphinic acid. The method makes accessible new substrates in the enzymatic production of L-glufosinate and its phosphoesters.
    Type: Grant
    Filed: March 28, 2022
    Date of Patent: November 19, 2024
    Assignee: Evonik Operations GmbH
    Inventors: Markus Pötter, Ludger Lautenschütz, Daniel Fischer, Jakob Müller
  • Patent number: 12129495
    Abstract: The present disclosure relates to engineered DNA polymerase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered DNA polymerase polypeptides. The present disclosure also provides methods of using the engineered DNA polymerase polypeptides or compositions thereof for diagnostic and other purposes.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: October 29, 2024
    Assignee: Codexis, Inc.
    Inventors: Ericka Bermudez, David Elgart, Nikki D. Kruse, Mathew G. Miller, Vesna Mitchell, Jovana Nazor, Nandhitha Subramanian
  • Patent number: 12129494
    Abstract: The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5?)ppp(5?)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: October 29, 2024
    Assignee: Codexis, Inc.
    Inventors: Mathew G. Miller, Chinping Chng, Oscar Alvizo, Melissa Ann Mayo, James Nicholas Riggins, Xiang Yi, Jonathan S. Penfield, Gjalt W. Huisman, Jared Davis, Yasushi Saotome
  • Patent number: 12116616
    Abstract: A method and kit are provided herein for determining the ADAMTS-13 activity in a sample. The method comprises contacting the sample with a von Willebrand factor (VWF) polypeptide which has been coupled to a reporter enzyme, such as glucose-6-phosphate dehydrogenase (G6PDH).
    Type: Grant
    Filed: May 15, 2023
    Date of Patent: October 15, 2024
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Herbert Schwarz, Frank Vitzthum
  • Patent number: 12116609
    Abstract: Described is a recombinant expression vector that enables a cell transformed to contain and express the vector to use levulinic acid as a carbon source, thereby converting levulnic acid into 2-butanne. Also described are genetically modified cells transformed to contain and express the vector and methods of using the cells to produce 2-butanone from a medium containing levulinic acid.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: October 15, 2024
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Brian Frederick Pfleger, Jacqueline Marie Rand, Christopher Robert Mehrer, Matthew Ryan Incha
  • Patent number: 12116600
    Abstract: The invention relates to engineered terminal deoxynucleotidyl transferase (TdT) enzymes or the homologous amino acid sequence of Pol?, Pol?, Pol?, and Pol? of any species or the homologous amino acid sequence of X family polymerases of any species and uses thereof.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: October 15, 2024
    Assignee: Nuclera Ltd.
    Inventors: Michael Chun Hao Chen, Sihong Chen, Gordon Ross McInroy
  • Patent number: 12110518
    Abstract: The invention relates to polypeptides having hydrolytic activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: October 8, 2024
    Assignee: Novozymes A/S
    Inventors: Ming Li, Jesper Salomon, Dorotea Raventos Segura, Mary Ann Stringer, Rebecca Munk Vejborg, Dorte Marie Koefoed Klitgaard, Dorota Nissen, Wei Peng, Tianqi Sun
  • Patent number: 12098397
    Abstract: The invention generally relates to methods of producing loline alkaloids or precursors thereof, expression constructs, and host cells useful for producing loline alkaloids or precursors thereof, and methods for producing loline alkaloids or precursors thereof in a host cell.
    Type: Grant
    Filed: August 2, 2022
    Date of Patent: September 24, 2024
    Assignee: Biotelliga Holdings Limited
    Inventors: Damien James Fleetwood, Mikhail Fokin, Kelly Alexander Styles, Amritha Suhasini Wickramage, Sanjay Saikia
  • Patent number: 12098407
    Abstract: Provided herein are compositions and methods for uncoupling the yield and productivity of an isoprenoid compound produced in a host cell. In some embodiments, the yield and productivity are uncoupled by genetically modifying the host cell to reduce flux through the citric acid cycle (TCA). In other embodiments, the yield and productivity are uncoupled by reducing the levels of ATP in the host cell.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: September 24, 2024
    Assignee: Amyris Inc.
    Inventors: Penelope R. Chua, Joshua Adam Lerman, Thomas Jon Scherbart, Chandresh Thakker, Annie Ening Tsong, Hanxiao Jiang
  • Patent number: 12077786
    Abstract: Described herein are compositions and methods for identifying, selecting, or culturing cells comprising a subject nucleic acid sequence of interest. Generally, a nucleic acid comprising a subject nucleic acid and a sequence encoding an enzyme molecule involved in biosynthesis of an amino acid is introduced into a cell. The cell is then grown on media lacking the amino acid, such that cells comprising the introduced nucleic acid are capable of growth. In some instances, the cell further comprises an inhibitor of the enzyme molecule to increase the stringency of the selection.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: September 3, 2024
    Assignee: LONZA LTD
    Inventors: Robert Young, Christopher Mark Smales, Colin Mark Jaques, Andrew J. Racher, Gurdeep Singh, James Budge, Joanne Robool
  • Patent number: 12071612
    Abstract: The present disclosure relates to the technical field of microorganisms, in particular to Lactobacillus gasseri HMV18 and a secreted protein and an application thereof. The Lactobacillus gasseri HMV18 is preserved in the China Center for Type Culture Collection on Jul. 11, 2019 with a preservation number of CCTCC NO: M 2019538, and a preservation address of Wuhan University, Wuhan, China. The protein extracted from the Lactobacillus gasseri HMV18 has antibacterial and anti-tumor effects, but basically has no effect on normal myocardial cells, so the Lactobacillus gasseri HMV18 can be applied to preparation of antibacterial and anti-tumor products.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: August 27, 2024
    Assignee: Hebei Medical University
    Inventors: Bin Cong, Xianxian Jia
  • Patent number: 12065677
    Abstract: A microorganism is transformed to be capable of producing guanidinoacetic acid (GAA). A method can be used for the fermentative production of GAA using such a microorganism. A corresponding method can be used for the fermentative production of creatine.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: August 20, 2024
    Assignee: Evonik Operations GmbH
    Inventors: Frank Schneider, Frank Jankowitsch
  • Patent number: 12065676
    Abstract: Provided herein, in some embodiments, are engineered cells and use of the same for increased hydrogen production. In particular, provided herein are genetically engineered cells comprising a polynucleotide encoding a fusion protein comprising a photosystem I (PSI) protein and an algal hydrogenase, as well as methods for producing such genetically engineered cells. Also provided herein are methods for increasing hydrogen (H2) production in cells.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: August 20, 2024
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Kevin Redding, Andrey Kanygin
  • Patent number: 12054751
    Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.
    Type: Grant
    Filed: December 15, 2022
    Date of Patent: August 6, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Darya Burakov, James P. Fandl
  • Patent number: 12043860
    Abstract: Exemplary embodiments provided herein include genetically engineering microorganisms, such as yeast or bacteria, to produce cannabinoids by inserting genes that produce the appropriate enzymes for the metabolic production of a desired compound.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: July 23, 2024
    Assignee: Lygos, Inc.
    Inventors: Jason L. Poulos, Anthony N. Farina
  • Patent number: 12037610
    Abstract: The present disclosure relates to a polypeptide having an acyltransferase activity or a microorganism including the same; a composition for preparing N-acetyl-L-methionine, the composition including the polypeptide or microorganism; and a method of preparing N-acetyl-L-methionine using the polypeptide or microorganism. Further, the present disclosure relates to a polynucleotide encoding the polypeptide and an expression vector including the polynucleotide. Since the microorganism including a novel acyltransferase according to the present disclosure has enhanced acyltransferase activity, this microorganism can be efficiently used for producing N-acetyl-L-methionine by acetylating L-methionine.
    Type: Grant
    Filed: October 27, 2021
    Date of Patent: July 16, 2024
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: So Yeon Hong, Jinseung Park, Hye Min Park, Su Jin Choi, Jun Ok Moon, Sung Gun Lee, Jinwoo Jeon
  • Patent number: 12031163
    Abstract: The present disclosure relates to liquid enzyme formulations containing one or more alpha-amylases for use in starch processing, wherein the pH of the enzyme formulation is about pH 6.0-8.0, and methods of use thereof. The present disclosure further relates to methods of making a liquid enzyme formulation containing one or more alpha-amylase having improved stability, comprising titrating the pH of the liquid enzyme formulation to a range of pH 6.0-8.0.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: July 9, 2024
    Assignee: BASF Enzymes LLC
    Inventor: Yun Han
  • Patent number: 12018304
    Abstract: Host cells that are engineered to produce benzylisoquinoline alkaloid (BIAS) precursors, such as norcoclaurine (NC) and norlaudanosoline (NL), are provided. The host cells may have one or more engineered modifications selected from: a feedback inhibition alleviating mutation in a enzyme gene; a transcriptional modulation modification of a biosynthetic enzyme gene; an inactivating mutation in an enzyme; and a heterologous coding sequence. Also provided are methods of producing a BIA of interest or a precursor thereof using the host cells and compositions, e.g., kits, systems etc., that find use in methods of the invention.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: June 25, 2024
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael Shareef Siddiqui, Christina D. Smolke
  • Patent number: 12012620
    Abstract: The present invention provides engineered peroxidase enzymes, polypeptides having peroxidase activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing peroxidase enzymes are also provided. The present invention further provides compositions comprising the peroxidase enzymes and methods of using the engineered peroxidase enzymes. The present invention finds particular use in the production of pharmaceutical and other compounds.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: June 18, 2024
    Assignee: Codexis, Inc.
    Inventors: Da Duan, Auric Anthony Sowell-Kantz, Aksiniya Lyubenova Petkova, Jovana Nazor, Nandhitha Subramanian, Oscar Alvizo
  • Patent number: 12012618
    Abstract: The present invention provides engineered galactose oxidase (GOase) enzymes, polypeptides having GOase activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing GOase enzymes are also provided. The present invention further provides compositions comprising the GOase enzymes and methods of using the engineered GOase enzymes. The present invention finds particular use in the production of pharmaceutical and other compounds.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: June 18, 2024
    Assignee: Codexis, Inc.
    Inventors: Christopher Michael Micklitsch, Oscar Alvizo, Jovana Nazor, Harvinder Chagger Maniar, Mikayla Jianghongxia Krawczyk, Margie Tabuga Borra-Garske, Nandhitha Subramanian, Anna Fryszkowska, Nicholas M. Marshall, Agustina Rodriguez-Granillo, Deeptak Verma, Dewan Andrews